This article discusses the use of positron emission tomography and computed tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose (F-FDG PET/CT) for early identification, staging, and efficacy evaluation of lung cancer. Lung cancer is the primary cause of death worldwide, and early diagnosis and treatment are crucial for improving survival rates. PET/CT, a non-invasive imaging technology, provides comprehensive information for diagnosis and treatment of various types of cancer, including lung cancer. F-FDG, a glucose analog, is the most commonly used imaging agent for PET/CT examinations.
Previous ArticleInsurance Platform Market
Next Article The Evolution Of Mobility: Mobility 2050